Top Stocks To Buy For 2014

Houston-based Parker Drilling Co. (NYSE: PKD  ) has a new CFO.

On Thursday, Parker announced that it has hired away offshore driller Ensco plc's vice president and treasurer, Christopher T. Weber, to become its own senior VP and Chief Financial Officer. Weber will take office on May 20.

Announcing the hire, Parker CEO Gary Rich described Weber as having "an�impressive�record in developing and supporting the successful execution of�corporate strategies�that�create�meaningful and sustainable�value." He also said that he "possesses a well-rounded blend of advanced international finance and operations expertise as well as the proven ability to bring innovative solutions that are actionable and have a significant positive impact."

In moving up in position, Weber is moving down in size. At Ensco, he was treasurer for an offshore driller boasting $4 billion in annual revenues. At Parker, he'll be responsible for all financial operations at a firm with less than $700 million in annual revenues.

10 Best Quality Stocks To Own Right Now: Glacier Bancorp Inc. (GBCI)

Glacier Bancorp, Inc., a multi-bank holding company, provides commercial banking services in Montana, Idaho, Wyoming, Colorado, Utah, and Washington. It offers transaction and savings deposits; real estate, commercial, agriculture, and consumer loans; mortgage origination services; and retail brokerage services to individuals, small to medium-sized businesses, community organizations, and public entities. The company�s deposit products include non-interest bearing demand accounts, interest bearing checking accounts, regular statement savings accounts, money market deposit accounts, fixed rate certificates of deposit, negotiated-rate jumbo certificates, individual retirement accounts, and reciprocal deposits. Its loan products comprise construction and permanent loans on residential real estate; consumer land and lot acquisition loans; unimproved land and land development loans; residential builder guidance lines comprising pre-sold and spec-home construction, and lot acqu isition loans; commercial real estate loans to purchase, construct, and finance commercial real estate properties; commercial and industrial loans; consumer loans secured by real estate, automobiles, and other assets; second mortgage and home equity loans; and agriculture loans. The company operates 106 locations, including 97 branches. Glacier Bancorp, Inc. was founded in 1955 and is headquartered in Kalispell, Montana.

Advisors' Opinion:

• [By Eric Volkman]

  Glacier Bancorp (NASDAQ: GBCI  ) is reaching into its vault for more cash to return to shareholders. The company this week declared its latest dividend, which is to be $0.15 per share paid on July 18 to shareholders of record as of July 9.

Top Stocks To Buy For 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Keith Speights]

  Sometimes, even the hint of an unfavorable regulatory decision can impact a biotech stock. Sarepta Therapeutics (NASDAQ: SRPT  ) shares lost more than 25% of their value in April. There wasn't an outright adverse FDA decision in this case. Instead, the FDA requested additional information related to a potential accelerated approval for Duchenne muscular dystrophy drug eteplirsen.

Top Stocks To Buy For 2014: Alumina Ltd (AWCMF)

Alumina Limited (Alumina), is an Australia-based company. The Company is the holding company of WMC Group. Alumina is engaged in investing in bauxite mining, alumina refining and selected aluminum smelting operations, through its 40% ownership of Alcoa World Alumina and Chemicals (AWAC). The Company�� partner, Alcoa, owns the remaining 60% of AWAC, and is the manager. The Company�� subsidiaries include Alumina Finance Limited, Alumina Holdings (USA) Inc., Alumina International Holdings Pty. Ltd., Alumina Brazil Holdings Pty Ltd, Alumina Limited Do Brasil SA, Alumina (U.S.A.) Inc., Butia Participacoes SA, Westminer Acquisition (U.K.) Limited, Westminer International (U.K.) Limited and Westminer (Investments) B.V. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks nudged modestly higher early Thursday, with a rebound for financials offsetting weakness in the resource space. The S&P/ASX 200 (AU:XJO) advanced 0.1% to 5,361.80, as banks and brokers gained after losing ground late in the previous session on concerns about the health of major Chinese banks. Commonwealth Bank of Australia (AU:CBA) (CBAUF) and Macquarie Group Ltd. (AU:MQG) (MCQEF) rose 0.7% apiece, Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) added 0.5%, and Westpac Banking Corp. (AU:WBC) (WEBNF) improved by 0.5%. On the downside, losses for gold futures overnight sent Newcrest Mining Ltd. (AU:NCM) (NCMGF) down 1.3% and Evolution Mining Ltd. (AU:EVN) (CAHPF) 2.3% lower. The broader mining sector was also lower, with Alumina Ltd. (AU:AWC) (AWCMF) off 2.8%, BHP Billiton Ltd. (AU:BHP) (BHP) down 0.5%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF)

Top Stocks To Buy For 2014: United States Steel Corporation(X)

United States Steel Corporation produces and sells steel mill products in North America and Central Europe. It operates in three segments: Flat-rolled Products (Flat-rolled), U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-rolled segment offers slabs, rounds, strip mill plates, sheets, and tin mill products, as well as iron ore and coke. This segment serves service center, conversion, transportation, construction, container, and appliance and electrical markets in North America. The USSE segment offers slabs, sheets, strip mill plates, tin mill products, and spiral welded pipes, as well as heating radiators and refractory ceramic materials. This segment serves the European construction, service center, conversion, container, transportation, and appliance and electrical, as well as and oil, gas, and petrochemical markets. The Tubular segment offers seamless and electric resistance welded steel casing and tubing; and standard, and line pipe and mechanical tubing. It primarily serves customers in the oil, gas, and petrochemical markets. The company also provides transportation services, including railroad and barge operations. In addition, it owns, develops, and manages various real estate assets, which include approximately 200,000 acres of surface rights primarily in Alabama, Illinois, Maryland, Michigan, Minnesota, and Pennsylvania; participates in joint ventures that are developing real estate projects in Alabama, Maryland, and Illinois; and owns approximately 4,000 acres of land in Ontario, Canada. The company was founded in 1901 and is headquartered in Pittsburgh, Pennsylvania.

Advisors' Opinion:

• [By Alex Planes]

  Theodore Roosevelt's ascent to the presidency following President William McKinley's assassination revived the Sherman Antitrust Act from near-death, and it was finally used to dismantle a company in 1904. That year, the Northern Securities railroad trust -- controlled by J.P. Morgan and John D. Rockefeller, among others -- was found to control an unreasonably large part of American railroad traffic, and was broken back up into its component railroads. This reestablished the Act as a potent weapon against monopolies, and it was used many times over the following century against major companies, if not always successfully. Here are some of the landmark decisions issued under an interpretation of the Sherman Antitrust Act, with brief explanations provided below (you can also click on their links for more information):

  Standard Oil Co. of New Jersey v. United States, 1911. United States v. Alcoa (NYSE: AA  ) , 1945. United States v. AT&T (NYSE: T  ) , 1982. United States v. United States Steel (NYSE: X  ) , 1920. United States v. Microsoft (NASDAQ: MSFT  ) , 2001. United States v. American Tobacco, 1911.

  The Standard Oil breakup in 1911 is the most important turning point of the Act's early history. It set a standard for "reasonableness" that has since been applied many times to determine what made a monopoly truly anticompetitive. Between this decision and the one that broke the American Tobacco trust several weeks later, the Supreme Court of 1911 is responsible for creating three long-tenured members of the Dow Jones Industrial Average (DJINDICES: ^DJI  ) -- two of which (both oil companies) are still on the index today.

• [By Ben Levisohn]

  That dynamic means that companies that can benefit from construction strength and cut costs will outperform others. For that reason, Murphy keeps Nucor (NUE) and�Steel Dynamics (STLD) at Buy. He wasn’t so kind to Reliance Steel (RS), US Steel (X) and AK Steel (AKS), which were all cut, though for different reasons.

Top Stocks To Buy For 2014: GSV Capital Corp (GSVC)

GSV Capital Corp. (GSV Capital), formerly NeXt Innovation Corp., is a development-stage company. The Company is an externally managed, non-diversified closed-end management investment company. The Company�� investment objective is to maximize capital appreciation. The Company will seek to achieve its investment objective by investing primarily in privately held high growth venture backed companies and select mid cap and large cap publicly traded companies.

The Company may also invest in select publicly-traded equity securities of companies that otherwise meet its investment criteria. It seeks to acquire its investments primarily through private secondary market transactions and, to a lesser extent, through transactions executed on public securities exchanges and direct investments in its portfolio companies. The Company�� investment activities will be managed by GSV Asset Management. GSV Capital Service Company will provide the administrative services.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Financial sector was the leading decliner in the US market today. Top losers in the sector included GSV Capital (NASDAQ: GSVC), off 9.3 percent, and Cninsure (NASDAQ: CISG), down around 6.6 percent.

• [By Helix Investment Research]

  Keating Capital is far from the only publicly traded pre-IPO investment company. There are several others, including GSV Capital (GSVC) and Firsthand Technology Value Fund (SVVC). Hercules Technology Growth Capital (HTGC) is also a pre-IPO fund, but with the bulk of its assets (over 92%) invested into loans to and debt of private companies, as opposed to their equity, the company's investment philosophy is different than that of these other pre-IPO funds. Unlike GSV Capital and Firsthand, Keating Capital, as a matter of policy, always purchases equity directly from portfolio companies, never from secondary markets such as SharesPost or SecondMarket. Mr. Keating outlined that this is due to the company's requirement that it be given access to all relevant financial data and managerial projections of its portfolio companies at all times, something that Mr. Keating believes is essential to being able to make informed investor decisions. We note that shares of Facebook (FB) and Twitter are conspicuously absent from Keating Capital's portfolio; the company declined to purchase shares of either company due to an inability to acquire direct financial information regarding these companies. In addition, Keating Capital has a stated goal of investing in the most senior equity securities available at each portfolio company.

Top Stocks To Buy For 2014: Remy International Inc (REMY)

Remy International, Inc. (Remy), incorporated on November 22, 1993, is a global vehicular parts designer, manufacturer, remanufacturer, marketer and distributor of aftermarket and original equipment electrical components for automobiles, light trucks, heavy-duty trucks and other vehicles. Remy sells its products worldwide primarily under the Delco Remy, Remy, and World Wide Automotive brand names. The Company�� products include light-duty and heavy-duty starters and alternators for both the original equipment and the remanufactured markets, and hybrid power technology. These products are principally sold or distributed to original equipment manufacturers (OEMs) for both original equipment manufacture and aftermarket operations, as well as to warehouse distributors and retail automotive parts chains. The Company sells its products principally in North America, Europe, Latin America and Asia-Pacific. In January 2014, Remy International, Inc. acquired all assets of USA Industries.

The Company�� original equipment division consists of three primary channels: automotive, heavy-duty vehicles and electric motors for electric and hybrid applications. Remy is a supplier for such original equipment manufacturers as General Motors, DaimlerChrylser, Toyota, Honda and Hyundai/Kia. The Company is a supplier of original equipment and aftermarket starters and alternators for heavy-duty vehicles in North America. Remy is an independent production electric motor supplier and in many aspects of hybrid and electric vehicle technology, including the patented hairpin stator technology. Its original equipment (OE) business has operations in the United States, Mexico, Brazil, China and Korea.

Advisors' Opinion:

• [By Rich Smith]

  On Monday, auto parts maker Remy International (NASDAQ: REMY  ) announced that it is taking 100% control of its Remy Hubei Electric Co. (REH) joint venture, buying out partner Hubei Super Electric Auto Motor Company's 49% interest in the JV.